Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 8.7% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NTLA) saw a bullish movement in the market today.

Why is Intellia Therapeutics, Inc. going up?

NTLA stock is up 8.7% on Feb 13, 2026 16:27

• The FDA's decision to lift the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran was a significant positive driver for the stock, leading to a notable increase in share price.
• Despite this positive development, concerns about the company's profitability and high price-to-sales ratio relative to industry averages have sparked discussions about the stock's valuation and future growth prospects.
• Analysts, on average, recommend holding the stock with a price target of $18.00. Insider selling and institutional ownership changes contribute to the mixed outlook on NTLA's valuation and potential future performance.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

A Look At Intellia Therapeutics (NTLA) Valuation After FDA Lifts Clinical Hold On Key Phase 3 Trial

Intellia Therapeutics (NTLA) saw its shares rise significantly after the FDA lifted a clinical hold on its MAGNITUDE-2 Phase 3 trial. While a strong "undervalued" narrative suggests a fair value of $173.99 based on aggressive future growth assumptions, the company is currently loss-making with a high price-to-sales ratio compared to industry averages. This creates a debate on whether the current valuation reflects an early opportunity or leaves little room for error if future execution falters.

https://www.sahmcapital.com/news/content/a-look-at-intellia-therapeutics-ntla-valuation-after-fda-lifts-clinical-hold-on-key-phase-3-trial-2026-02-08

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Hold" by Analysts

Intellia Therapeutics (NASDAQ:NTLA) has received a consensus "Hold" rating from twenty-one research firms, with an average 12-month price target of $18.00. Several analysts have recently cut their price targets for the gene-editing company. Insiders, including CEO John M. Leonard, have sold shares, reducing insider ownership, while institutional investors hold a significant portion of the stock.

https://www.marketbeat.com/instant-alerts/intellia-therapeutics-inc-nasdaqntla-given-average-recommendation-of-hold-by-analysts-2026-02-09/

A Look At Intellia Therapeutics (NTLA) Valuation After FDA Lifts Clinical Hold On Key Phase 3 Trial

Intellia Therapeutics (NTLA) is back in focus following the FDA's removal of a clinical hold on its MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran, prompting a significant increase in its share price. While the stock has seen recent gains and is considered "92.9% Undervalued" by a popular narrative that projects a fair value of $173.99, other analyses highlight a steep price-to-sales ratio, suggesting potential overvaluation or high expectations. Investors are now evaluating whether the FDA news creates a new entry point that justifies future growth assumptions given the company is still loss-making.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/a-look-at-intellia-therapeutics-ntla-valuation-after-fda-lif

Intellia Therapeutics (NTLA) Is Down 6.6% After FDA Lifts Hold On Key ATTRv-PN Trial – Has The Bull Case Changed?

Intellia Therapeutics saw its stock drop 6.6% despite the FDA lifting the clinical hold on its MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran (nex-z), intended for ATTRv-PN patients. This decision allows the trial to resume enrollment, presenting a key clinical catalyst, although the ATTR-CM MAGNITUDE trial remains on hold due to liver safety concerns. The company's investment narrative remains heavily reliant on the success of its gene-editing therapies, with significant investor focus on clinical execution and regulatory confidence given ongoing losses and a volatile stock price.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-is-down-66-after-fda-lifts-hold-o

Trending Today

Ethereum ($ETH) Crypto Forecast: Up 6.6% Today

Solana ($SOL) Crypto Forecast: Up 7.9% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.1% Today

Albemarle Corporation ($ALB) Stock Forecast: Up 5.8% Today

Sonos Inc. ($SONO) Stock Forecast: Down 5.2% Today

Franco-Nevada Corp. ($FNV) Stock Forecast: Up 5.1% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Up 7.6% Today

Rocket Companies Inc ($RKT) Stock Forecast: Up 5.1% Today

Jetblue Airways Corporation ($JBLU) Stock Forecast: Up 5.4% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Up 6.5% Today

Intellia Therapeutics, Inc. Price History

05.01.2026 - NTLA Stock was down 6.0%

• The decline in NTLA's stock value today might be due to investors selling to realize profits following a previous uptick in price.
• Despite receiving approval for its clinical trial and a raised price target, concerns about the company's long-term profitability may have shifted market sentiment.
• The market may be reacting to the company's ongoing losses despite positive regulatory news, causing uncertainty about its future financial performance.
• Investors might be wary of the continued clinical hold on the MAGNITUDE trial for ATTR-CM, which could be viewed as a risk factor affecting the stock's movement.

05.01.2026 - NTLA Stock was down 6.8%

• While the FDA lifted the clinical hold on Intellia's Phase 3 trial for hereditary transthyretin amyloidosis, the stock did not respond positively.
• Despite analysts raising price targets and institutional investors expressing optimism, the stock continued its bearish movement.
• Market reaction may have been influenced by ongoing concerns about a separate clinical hold on the cardiomyopathy study, overshadowing progress in the ATTRv-PN trial.
• Conflicting price targets provided by Baird and H.C. Wainwright possibly introduced uncertainty among investors, contributing to the stock's decline.

13.01.2026 - NTLA Stock was up 8.7%

• The FDA's decision to lift the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran was a significant positive driver for the stock, leading to a notable increase in share price.
• Despite this positive development, concerns about the company's profitability and high price-to-sales ratio relative to industry averages have sparked discussions about the stock's valuation and future growth prospects.
• Analysts, on average, recommend holding the stock with a price target of $18.00. Insider selling and institutional ownership changes contribute to the mixed outlook on NTLA's valuation and potential future performance.

04.01.2026 - NTLA Stock was down 5.7%

• The FDA lifting the clinical hold on Intellia's Phase 3 trial for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) was initially seen as a positive development, but the market reacted negatively, causing a 12.6% drop in the stock price.
• Despite the regulatory hurdle being cleared, investors may be concerned about the ongoing hold on the MAGNITUDE cardiomyopathy trial, leading to uncertainty about the company's future pipeline.
• Analysts providing varied ratings and decreased price targets could also contribute to the bearish sentiment, as the market digests the implications of the FDA decision and assesses the company's overall financial health and growth prospects.

27.00.2026 - NTLA Stock was up 5.8%

• NTLA stock soared by 10% today in a strong bullish movement.
• A clinical hold on one of Intellia's advanced gene therapy trials for ATTRv-PN was lifted by the FDA, allowing the company to restart patient enrollment.
• The FDA's approval to resume the trial has instilled confidence in Intellia's gene editing initiatives, leading to a notable surge in the stock price.
• Investors are keenly watching for further regulatory decisions on Intellia's clinical trials, especially concerning the ATTR amyloidosis program, which is expected to impact the stock's performance in the near term.

27.00.2026 - NTLA Stock was up 8.2%

• The rise in NTLA's stock price is linked to increased institutional investment from ARK Invest and positive updates on previous clinical hold concerns.
• CEO John Leonard's statement that a patient fatality in the nex-z program was not due to liver toxicity likely reassured investors and hinted at a potential lifting of the FDA hold, bolstering investor confidence.
• The upcoming regulatory decisions on the company's clinical trials, particularly regarding its hereditary angioedema (HAE) candidate, Lonvoguran Ziclumeran, are key points of interest for investors looking at future growth potential.
• Despite uncertainties around its ATTR amyloidosis program and mixed analyst ratings, ARK Invest's recent buying activity demonstrates investor optimism and readiness to handle the volatility often seen with biotech stocks like NTLA.

10.01.2026 - NTLA Stock was down 5.2%

• Despite recent developments in its MAGNITUDE-2 Phase 3 trial, Intellia Therapeutics (NTLA) saw a 6.6% decline in its stock price.
• Concerns over the ongoing hold on another trial, ATTR-CM MAGNITUDE, have affected investor confidence and contributed to the stock's bearish movement.
• Analysts' decision to maintain a "Hold" rating, reduce price targets, and insider selling have further impacted the sentiment surrounding NTLA's stock.
• The company's status as currently loss-making, alongside debates on its valuation, has led to increased stock volatility and caution among investors regarding future regulatory challenges.

22.00.2026 - NTLA Stock was up 5.8%

• NTLA saw a notable bullish trend today, potentially influenced by several key factors:
• A recent surge in the company's stock price and increased attention from ARK Investment and the J.P. Morgan Healthcare Conference have attracted investor interest.
• Varied signals on valuation, including indications of both undervaluation based on a DCF model and potential overvaluation suggested by a high P/S ratio, may have led to market volatility and trading possibilities.
• The generally optimistic outlook for the gene editing industry, underscored by anticipated market expansion and transformative prospects for genetic disease treatment, may have also bolstered NTLA's bullish movement.
• Investors weighing the risks associated with stock volatility, clinical trial results, and regulatory challenges within the gene editing market could have also contributed to NTLA's market performance.

28.00.2026 - NTLA Stock was down 8.8%

• NTLA saw a decline in its stock value as the FDA removed the clinical hold on one of its gene therapy trials for ATTRv-PN, causing uncertainty in the market.
• The ongoing hold on the trial for ATTR-CM due to severe side effects and a patient's death added to the pessimism surrounding NTLA.
• Despite the positive development of the FDA allowing the resumption of patient enrollment in one trial, concerns about regulatory issues and safety continued to impact NTLA's stock performance.
• Investors appear cautious about potential safety implications on NTLA's future trials and its ability to handle regulatory hurdles efficiently.

03.01.2026 - NTLA Stock was down 5.1%

• Despite the FDA lifting the clinical hold on Intellia's MAGNITUDE-2 Phase 3 trial for hereditary transthyretin amyloidosis, the stock plummeted 12.6%, reflecting investor apprehension.
• Diverse analyst ratings and price forecasts for NTLA, along with some analysts lowering their targets despite strong financial performance, likely impacted the downward trend.
• The market's attention towards the trial's advancement, upcoming regulatory developments, and existing clinical, regulatory, and financial uncertainties potentially contributed to the prevailing negative market outlook towards Intellia Therapeutics.

30.00.2026 - NTLA Stock was down 7.6%

• The FDA's decision to lift the clinical hold on Intellia's Phase III trial for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) resulted in a temporary boost in the stock price.
• However, the ongoing hold on the MAGNITUDE trial for cardiomyopathy patients, attributed to severe liver-related side effects, raised uncertainties and potential concerns among investors, contributing to the recent bearish trend.
• Despite the positive development of trial resumptions, persistent safety concerns and regulatory scrutiny surrounding Intellia's gene therapy programs likely influenced investor sentiment, leading to the bearish market activity.
• The diverse analyst ratings and the decrease in the average price target may have also impacted the downward movement, reflecting differing perspectives on the company's future despite its strong financial performance.

30.00.2026 - NTLA Stock was down 6.9%

• The FDA lifted a clinical hold on one of Intellia's late-stage gene therapy trials for hereditary transthyretin amyloidosis, allowing the company to resume patient enrollment. This news initially resulted in a 10% rise in shares.
• Despite the positive development regarding the lifted clinical hold, the bearish movement may be linked to the continued hold on another trial for ATTR-CM due to severe liver-related side effects, including a patient's death.
• Intellia's financial performance remains solid, with revenue growth and strong ratios. However, market sentiment could have been affected by uncertainties related to the paused trial and the necessity for new risk mitigation measures.
• Analysts have provided diverse ratings for Intellia Therapeutics, with some lowering price targets. This may be indicative of concerns about the regulatory obstacles facing the company, despite the promising nature of its gene-editing therapies.